相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Mobilization of Hematopoietic Progenitors from Normal Donors Using the Combination of Granulocyte-Macrophage Colony-Stimulating Factor and Granulocyte Colony-Stimulating Factor Results in Fewer Plasmacytoid Dendritic Cells in the Graft and Enhanced Donor T Cell Engraftment with Th1 Polarization: Results from a Randomized Clinical Trial
Sagar Lonial et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Cancer Statistics, 2012
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
Function but not phenotype of melanoma peptide-specific CD8+ T cells correlate with survival in a multiepitope peptide vaccine trial (ECOG 1696)
Carsten Schaefer et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Tumor Stem Cell Antigens as Consolidative Active Specific Immunotherapy: A Randomized Phase II Trial of Dendritic Cells Versus Tumor Cells in Patients With Metastatic Melanoma
Robert O. Dillman et al.
JOURNAL OF IMMUNOTHERAPY (2012)
Phase I Trial of bi-shRNAifurin/GMCSF DNA/Autologous Tumor Cell Vaccine (FANG) in Advanced Cancer
Neil Senzer et al.
MOLECULAR THERAPY (2012)
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
Steffen Walter et al.
NATURE MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
Steven A. Rosenberg et al.
CLINICAL CANCER RESEARCH (2011)
Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy
Jeong Heo et al.
MOLECULAR THERAPY (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma
Howard L. Kaufman et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma
Frederick Locke et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Active Immunotherapy Induces Antibody Responses That Target Tumor Angiogenesis
Jonathan Schoenfeld et al.
CANCER RESEARCH (2010)
Phase I/II Study of Oncolytic HSVGM-CSF in Combination with Radiotherapy and Cisplatin in Untreated Stage III/IV Squamous Cell Cancer of the Head and Neck
Kevin J. Harrington et al.
CLINICAL CANCER RESEARCH (2010)
Cytokine Working Group Study of Lymphodepleting Chemotherapy, Interleukin-2, and Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Metastatic Melanoma: Clinical Outcomes and Peripheral-Blood Cell Recovery
Krishna S. Gunturu et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Intranodal Immunization With a Vaccinia Virus Encoding Multiple Antigenic Epitopes and Costimulatory Molecules in Metastatic Melanoma
Michel Adamina et al.
MOLECULAR THERAPY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Immune Checkpoint Proteins: A New Therapeutic Paradigm for Cancer-Preclinical Background: CTLA-4 and PD-1 Blockade
Jeffrey Weber
SEMINARS IN ONCOLOGY (2010)
The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease
Timothy R. Hercus et al.
BLOOD (2009)
Malignant Melanoma Therapy by Chemotherapy and Autoimmunity Induced by Cytokine
Shi Jin et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2009)
Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Vaccination with an Allogeneic Whole-Cell Melanoma Vaccine
Mark B. Faries et al.
CLINICAL CANCER RESEARCH (2009)
Anti-Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors
Betty Li et al.
CLINICAL CANCER RESEARCH (2009)
Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial
Craig L. Slingluff et al.
CLINICAL CANCER RESEARCH (2009)
Immunogenicity and Antitumor Effects of Vaccination with Peptide Vaccine +/- Granulocyte-Monocyte Colony-Stimulating Factor and/or IFN-α2b in Advanced Metastatic Melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696
John M. Kirkwood et al.
CLINICAL CANCER RESEARCH (2009)
Phase II Multicenter Trial of Maintenance Biotherapy After Induction Concurrent Biochemotherapy for Patients With Metastatic Melanoma
Steven J. O'Day et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor-Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma
Neil N. Senzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A Phase 1 Study of Granulocyte Macrophage Colony-stimulating Factor (Sargramostim) and Escalating Doses of Thalidomide in Patients With High-risk Malignant Melanoma
Jose Lutzky et al.
JOURNAL OF IMMUNOTHERAPY (2009)
Recombinant Human Granulocyte-macrophage Colony-stimulating Factor (GM-CSF, Sargramostim) Administered for 3 Years as Adjuvant Therapy of Stages II(T4), III, and IV Melanoma
Lynn E. Spitler et al.
JOURNAL OF IMMUNOTHERAPY (2009)
Direct Injection of Protamine-protected mRNA: Results of a Phase 1/2 Vaccination Trial in Metastatic Melanoma Patients
Benjamin Weide et al.
JOURNAL OF IMMUNOTHERAPY (2009)
A Dose-Escalation Study of Aerosolized Sargramostim in the Treatment of Metastatic Melanoma An NCCTG Study
Svetomir N. Markovic et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2008)
Phase 1/2 dose-escalation study of a GM-CSF-Secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer
Celestial S. Higano et al.
CANCER (2008)
Sequential administration of GM-CSF (Sargramostim®) and IL-2 ± autologous vaccine as adjuvant therapy in cutaneous melanoma:: An interim report of a phase II clinical trial
E. George Elias et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2008)
Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor
Adil I. Daud et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Immunoembolization of Malignant Liver Tumors, Including Uveal Melanoma, Using Granulocyte-Macrophage Colony-Stimulating Factor
Takami Sato et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma:: final results of EORTC 18991, a randomised phase III trial
Alexander M. M. Eggermont et al.
LANCET (2008)
Phase I/II Study of GM-CSF DNA as an Adjuvant for a Multipeptide Cancer Vaccine in Patients With Advanced Melanoma
Miguel-Angel Perales et al.
MOLECULAR THERAPY (2008)
GM-CSF-secreting cancer immunotherapies: preclinical analysis of the mechanism of action
Andrew D. Simmons et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb
Betty Li et al.
CLINICAL IMMUNOLOGY (2007)
Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor based antitumor vaccine
Paola Filipazzi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF - Secreting cancer immunotherapy
Betty Li et al.
CLINICAL CANCER RESEARCH (2006)
A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor
Jennifer C. C. Hu et al.
CLINICAL CANCER RESEARCH (2006)
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
Sergio A. Quezada et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect
K-J Choi et al.
GENE THERAPY (2006)
Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-α2b, and recombinant interleukin-2 for the treatment of metastatic melanoma
RW Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Administration of IFN-α enhances the efficacy of a granulocyte macrophage colony stimulating factor-secreting tumor cell vaccine
RA Prell et al.
CANCER RESEARCH (2005)
MAGE-Al-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma
KA Chianese-Bullock et al.
JOURNAL OF IMMUNOLOGY (2005)
Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy
J Stagg et al.
CANCER RESEARCH (2004)
A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products
S Lonial et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2004)
Aerosolized granulocyte macrophage colony-stimulating factor (GM-CSF) therapy in metastatic cancer
RD Rao et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2003)
Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma
R Soiffer et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides
C Scheibenbogen et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: A randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma
JW Smith et al.
JOURNAL OF IMMUNOTHERAPY (2003)
ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties
BL Liu et al.
GENE THERAPY (2003)
Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFNα in patients with metastatic melanoma
GC de Gast et al.
BRITISH JOURNAL OF CANCER (2003)
Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells
CL Slingluff et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin-2, and interferon-alpha
G Groenewegen et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2002)
GM-CSF-based cellular vaccines: a review of the clinical experience
I Borrello et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2002)
Perilesional injection cutaneous melanoma of r-GM-CSF in patients with metastases
C Hoeller et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2001)
Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor
M Toda et al.
MOLECULAR THERAPY (2000)
Cytokine upregulation of the antigen presenting function of acute myeloid leukemia cells
MW Boyer et al.
LEUKEMIA (2000)
Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma
C Scheibenbogen et al.
JOURNAL OF IMMUNOTHERAPY (2000)
GM-CSF with biochemotherapy (cisplatin, DTIC, tamoxifen, IL-2 and interferon-alpha): A phase I trial in melanoma
MM Vaughan et al.
ANNALS OF ONCOLOGY (2000)
分享论文
